Atirmociclib (CDK4 Inhibitor)

April 21, 2026 — Pfizer Inc. (NYSE: PFE) announced it will present new oncology data at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, 2026, Chicago), spanning more than 40 company-, investigator-, and partner-sponsored abstracts, including three late-breaking sessions and eight oral/rapid oral presentations.

Key clinical updates highlighted include: a 7-year update from the Phase 3 CROWN study supporting LORBRENA (lorlatinib) as a guideline-recommended first-line therapy for ALK-positive metastatic NSCLC; late-breaking PFS and OS results from Cohort 3 of the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) + cetuximab + FOLFIRI as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer; and late-breaking Phase 3 TALAPRO-3 results showing clinically meaningful rPFS benefit and a strong OS trend for TALZENNA (talazoparib) + XTANDI (enzalutamide) in mCSPC with HRR gene alterations.

Pfizer also cited data supporting earlier-line use of TUKYSA (tucatinib) as first-line maintenance in HER2+ metastatic breast cancer and provided updates on pipeline assets including PF-08634404 (PD-1/VEGF bispecific), sigvotatug vedotin (ADC), and atirmociclib (CDK4 inhibitor), underscoring potential new standards of care and pipeline breadth.